HER2-low Breast Cancer Clinical Trials

8 recruiting

HER2-low Breast Cancer Trials at a Glance

8 actively recruiting trials for her2-low breast cancer are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Guangzhou, Boston, and Changsha. Lead sponsors running her2-low breast cancer studies include Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Renske Altena, and Daiichi Sankyo.

Browse her2-low breast cancer trials by phase

Treatments under study

About HER2-low Breast Cancer Clinical Trials

Looking for clinical trials for HER2-low Breast Cancer? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HER2-low Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HER2-low Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

HER2-low Breast Cancer
The First Affiliated Hospital with Nanjing Medical University37 enrolled1 locationNCT07446452
Recruiting
Phase 3

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

HER2-low Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.566 enrolled2 locationsNCT06957886
Recruiting

Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer

HER2-low Breast CancerHER2-positive Breast CancerTrastuzumab-rezetecan
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University300 enrolled1 locationNCT07358182
Recruiting

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Breast CancerHER2-low Breast CancerHER2-positive Breast Cancer+1 more
Daiichi Sankyo800 enrolled54 locationsNCT06210776
Recruiting

HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC

HER2-low Breast CancerBreast Cancer Stage IVMolecular Imaging
Renske Altena70 enrolled1 locationNCT06830382
Recruiting
Phase 2

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Breast CancerMetastatic Breast CancerHER2-low Breast Cancer+1 more
Ana C Garrido-Castro, MD357 enrolled11 locationsNCT06533826
Recruiting

Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer

Breast CancerHER2-low Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University255 enrolled1 locationNCT05466786
Recruiting

Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer

Breast NeoplasmsHER2-low Breast CancerAntibody-drug Conjugates
Sun Yat-sen University700 enrolled1 locationNCT06877416